NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 1,687.00
-3.00 (-0.18%)
At close: Apr 24, 2026
NGeneBio Revenue
In the year 2025, NGeneBio had annual revenue of 21.24B KRW with 278.54% growth. NGeneBio had revenue of 11.97B in the quarter ending December 31, 2025, with 1,780.38% growth.
Revenue
21.24B
Revenue Growth
+278.54%
P/S Ratio
2.13
Revenue / Employee
n/a
Employees
n/a
Market Cap
45.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.24B | 15.63B | 278.54% |
| Dec 31, 2024 | 5.61B | 1.26B | 28.96% |
| Dec 31, 2023 | 4.35B | -6.67B | -60.51% |
| Dec 31, 2022 | 11.02B | 3.85B | 53.81% |
| Dec 31, 2021 | 7.16B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 32.97B |
| ADBiotech | 12.90B |
| MOA Life Plus | 11.22B |
| Eutilex.Co.,Ltd | 10.29B |
| HLB Pep | 4.96B |
| EyeGene | 3.57B |
| SCM Lifescience | 1.54B |
| Kainos Medicine | 1.17B |